Systems, Pathways and Targets Program (SPT)

系统、路径和目标 摘要/项目摘要 系统、途径和目标（SPT）计划的首要目标是发现新的关键机制。 癌症的增殖、存活和耐药性，可以用来开发新的治疗方法， 和诊断。小组委员会成员包括细胞生物学家、免疫学家、遗传学家、系统生物学家， 计算科学家和临床医生，他们利用不同的观点来建立协作团队， 用大胆和创新的方法解决长期存在的癌症问题。小组委员会成员在不同的 从分子和细胞到组织和器官，研究个体癌症的基本生物学 细胞以及肿瘤环境和转移部位中细胞之间的相互作用。小组委员会的几名成员是 拥有独立研究计划的医生科学家，并且能够将发现从 长凳到床边此外，小组委员会的领导层通过疾病- 定向团队（DOT）和年度CFCCC科学务虚会。这些相互作用导致了新的临床试验 并为研究项目提供获取患者样本的便利。小组委员会的一个独特之处是， 系统生物学方法研究癌症。这一新出现的重点导致了富有成效的内部- 和跨计划合作和校外资助，包括NCI-U 54赠款，以支持一个中心， 癌症系统生物学SPT最大限度地提高了癌症治疗靶点识别的进展 通过投入资源招聘新的教职员工，培养早期职业发展， 教师，并支持职业中期的教师与尖端的研究计划，重点是癌细胞 生物学和治疗靶向。为促进协作，小组委员会支持各工作组， 兴趣和赞助商会议和讲习班。小组委员会的具体目标是： 信号网络、发育途径和与癌症发生相关的代谢程序， 进展和治疗耐药性;支持多学科团队研究异质性如何在 单细胞水平和细胞-细胞相互作用可影响癌症进展和治疗抗性;以及 通过DOT实现临床基础科学多学科研究，以加速临床前 research.这些发现关键途径和生存机制的努力将揭示新的治疗方法， 在临床前模型中进行测试和验证的目标，并最终在临床试验中。 成员：来自16个部门和5所学校的72名成员 资金：$3，467，881 NCI（直接）;$7，256，055其他同行评审（直接） 累积：干预性：133;治疗：130;机构/研究者发起：98 出版物：总数：793;高影响力期刊：199（25%）;方案内：113（14%）; 方案间：106（13%）;机构间：504（64%）

SYSTEMS, PATHWAYS & TARGETS PROGRAM ABSTRACT/PROJECT SUMMARY The overarching goal of the Systems, Pathways & Targets (SPT) Program is to discover new critical mechanisms of cancer proliferation, survival and drug resistance that can be exploited for the development of novel treatments and diagnostics. SPT members include cell biologists, immunologists, geneticists, systems biologists, computational scientists, and clinicians who leverage diverse perspectives to build collaborative teams that tackle long-standing problems in cancer using bold and innovative approaches. SPT members work at different scales, from molecules and cells to tissues and organs, to study the fundamental biology of individual cancer cells and the interactions among cells in the tumor environment and metastatic sites. Several SPT members are physician-scientists with independent research programs and are well-positioned to translate discoveries from bench to bedside. Moreover, SPT leadership actively connects basic scientists with clinicians through Disease- Oriented Teams (DOTs) and the annual CFCCC Scientific Retreat. These interactions lead to new clinical trials and facilitate access to patient samples for research projects. A unique aspect of SPT is the integration of systems biology approaches to the study of cancer. This emerging emphasis has resulted in productive intra- and inter-programmatic collaborations and extramural funding including a NCI-U54 grant to support a Center in Cancer Systems Biology. SPT maximizes progress toward the identification of targets for cancer therapeutics and diagnostics by devoting resources to recruiting new faculty members, nurturing development of early career faculty, and supporting mid-career faculty members with cutting-edge research programs focused on cancer cell biology and therapeutic targeting. To promote collaboration, SPT supports working groups with shared interests and sponsors conferences and workshops. The Specific Aims of SPT are: to identify key targets in signaling networks, developmental pathways, and metabolic programs that are relevant to cancer initiation, progression, and therapeutic resistance; to support multidisciplinary teams that study how heterogeneity at the single cell level and cell-cell interactions can influence cancer progression and therapeutic resistance; and to enable clinical-basic science multidisciplinary research via DOTs to accelerate the translation of preclinical research. These efforts to discover critical pathways and survival mechanisms will reveal novel therapeutic targets for testing and validation in preclinical models, and eventually in clinical trials. Membership: 72 Members from 16 Departments and 5 Schools Funding: $3,467,881 NCI (Directs); $7,256,055 Other Peer-Reviewed (Directs) Accruals: Interventional: 133; Treatment: 130; Institutional/Investigator-Initiated: 98 Publications: Total: 793; High Impact Journal: 199 (25%); Intra-programmatic: 113 (14%); Inter-Programmatic: 106 (13%); Inter-Institutional: 504 (64%)